ESTRO 2024 - Abstract Book

S1286

Clinical - Head & neck

ESTRO 2024

Material/Methods:

Records of 1031 patients with oropharyngeal carcinoma and 196 patients with hypopharyngeal carcinoma who were referred for radical or adjuvant treatment to a single oncological centre from January 2010 to December 2022 were evaluated. Out of these, posterior oropharyngeal wall was the primary subsite of 17 patients out of 1031 (1.65%) and posterior hypopharyngeal wall was the primary subsite of 23 patients out of 196 (11.73%). These 40 patients are the subjects of further analysis and local control and survival was evaluated.

Results:

For Oropharyngeal tumours, radical treatment was given to 16 patients, 1 patient was treated in adjuvant setting. 4 were treated using 3D-CRT and 13 using IMRT. Concurrent cispaltin chemotherapy was used in 8 patients. For hypopharyngeal tumours, radical treatment was given to 21 patients, 2 patients were treated in adjuvant setting. 5 were treated using 3D-CRT and 18 using IMRT. Concurrent cispaltin chemotherapy was used in 13 patients.

p16 IHC was negative in 14 patients, positive in 1 patient and not available in 3 patients with oropharyngeal tumours.

Local recurrence developed in 4 patients (23.5%) in median 4 months (range: 2 – 8 months) and in 8 patients (34.7%) in median of 20 months (range: 7 – 88 months) for oropharyngeal and hypopharyngeal tumours respectively. Distant metastasis developed 4 patients in median time of 7.5 months (range 2 - 17 months) and in 3 patients in median time of 16 months (range 11 – 20 months) for oropharyngeal and hypopharyngeal tumours respectively. 2 patients in each group developed distant metastasis synchronously with local recurrence. The median overall survival for posterior pharyngeal wall tumours of oro-pharynx and hypo-pharynx was 36 months and 68 months respectively. Grade 3/4 dysphagia was seen in 3 (18%) and 6 (26%) of patients oropharyngeal and hypopharyngeal tumours respectively.